Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial
Latest Information Update: 19 Dec 2024
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Yttrium-90
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms MacroTrans
- 18 Dec 2024 New trial record
- 16 Dec 2024 Planned initiation date changed from 1 Jan 2025 to 1 Dec 2024.
- 16 Dec 2024 Status changed from not yet recruiting to recruiting.